Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Leqvio®: US launch underway
FDA approved
C
E
AZ
K&K
LEQVIO®
Effective and sustained LDL-C reduction¹
with twice a year maintenance dose
administered by HCP
Broad label covering 16m US ASCVD
patients not at LDL-C goal
Go-to-market model designed to overcome
clinical barriers and address access,
adherence and affordability
Sales, reimbursement and medical field
teams trained and deployed
Robust network of AICs to provide acquisition
and administration flexibility
Value-based price per dose of USD 3,250
Comprehensive patient and HCP support programs
available to ensure timely access
Product available from specialty distributors since
early January
Filed for permanent J-Code, miscellaneous J-Code
for temporary use available
Expect modest initial ramp as we lay the foundation for multi-blockbuster potential
LDL-C - Low Density Lipoprotein Cholesterol ASCVD Atherosclerotic Cardiovascular Disease AIC - Alternative Injection Center HCP Healthcare Professional 1. Across the 6-month dosing interval.
30 Investor Relations | Q4 2021 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation